Is the Genetic Background of Co-Stimulatory CD28/CTLA-4 Pathway the Risk Factor for Prostate Cancer?
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1532-2807
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Is the Genetic Background of Co-Stimulatory CD28/CTLA-4 Pathway the Risk Factor for Prostate Cancer? ; day:18 ; month:1 ; year:2017 ; pages:1-7
Pathology & oncology research ; (18.1.2017), 1-7
- Keyword
-
Krebs
Onkologie
- Creator
-
Karabon, Lidia
- Contributor
-
Tupikowski, K.
Tomkiewicz, A.
Partyka, A.
Pawlak-Adamska, E.
Wojciechowski, A.
Kolodziej, A.
Dembowski, J.
Zdrojowy, R.
Frydecka, I.
SpringerLink (Online service)
- DOI
-
10.1007/s12253-016-0180-4
- URN
-
urn:nbn:de:1111-201702155949
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:57 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Karabon, Lidia
- Tupikowski, K.
- Tomkiewicz, A.
- Partyka, A.
- Pawlak-Adamska, E.
- Wojciechowski, A.
- Kolodziej, A.
- Dembowski, J.
- Zdrojowy, R.
- Frydecka, I.
- SpringerLink (Online service)
Other Objects (12)
Einfluss von CD28- und CTLA-4-Mutationen auf die T-Zellaktivierung
Generation and characterization of CD19 CAR T cells with CTLA-4/CD28 fusion receptor
CD28/CTLA-4/ICOS haplotypes confers susceptibility to Graves’ disease and modulates clinical phenotype of disease
sCD163, sCD28, sCD80, and sCTLA-4 as soluble marker candidates for detecting immunosenescence
Blockade ofthe negative co-stimulatory molecules PD-1 and CTLA-4 improves survival in primary and secondary fungal sepsis
Differential regulation of motility and immune synapses by CD28/ CTLA-4 costimulation in effector and regulatory T cells
Sequencing CTLA-4 blockade with cell-based immunotherapy for prostate cancer
Double strike approach for tumor attack: Engineering T cells using CD40L:CD28 chimeric co-stimulatory proteins for enhanced tumor targeting in adoptive cell therapy
Immunotherapies targeting stimulatory pathways and beyond
Combined targeting of co-stimulatory (OX40) and co-inhibitory (CTLA-4) pathways elicits potent effector T cells capable of driving robust anti-tumor immunity
Inhibition of STAT3 augments antitumor efficacy of anti-CTLA-4 treatment against prostate cancer
Vergleich der Rolle kostimulatorischer Moleküle (CTLA-4, CD28) bei der anti-CD40 und Interleukin-4 vermittelten IgE-Produktion von Normalpersonen und Atopikern
Einfluss von CD28- und CTLA-4-Mutationen auf die T-Zellaktivierung
Generation and characterization of CD19 CAR T cells with CTLA-4/CD28 fusion receptor
CD28/CTLA-4/ICOS haplotypes confers susceptibility to Graves’ disease and modulates clinical phenotype of disease
sCD163, sCD28, sCD80, and sCTLA-4 as soluble marker candidates for detecting immunosenescence
Blockade ofthe negative co-stimulatory molecules PD-1 and CTLA-4 improves survival in primary and secondary fungal sepsis
Differential regulation of motility and immune synapses by CD28/ CTLA-4 costimulation in effector and regulatory T cells
Sequencing CTLA-4 blockade with cell-based immunotherapy for prostate cancer
Double strike approach for tumor attack: Engineering T cells using CD40L:CD28 chimeric co-stimulatory proteins for enhanced tumor targeting in adoptive cell therapy
Immunotherapies targeting stimulatory pathways and beyond
Combined targeting of co-stimulatory (OX40) and co-inhibitory (CTLA-4) pathways elicits potent effector T cells capable of driving robust anti-tumor immunity
Inhibition of STAT3 augments antitumor efficacy of anti-CTLA-4 treatment against prostate cancer
Vergleich der Rolle kostimulatorischer Moleküle (CTLA-4, CD28) bei der anti-CD40 und Interleukin-4 vermittelten IgE-Produktion von Normalpersonen und Atopikern
Einfluss von CD28- und CTLA-4-Mutationen auf die T-Zellaktivierung
Generation and characterization of CD19 CAR T cells with CTLA-4/CD28 fusion receptor
CD28/CTLA-4/ICOS haplotypes confers susceptibility to Graves’ disease and modulates clinical phenotype of disease
sCD163, sCD28, sCD80, and sCTLA-4 as soluble marker candidates for detecting immunosenescence
Blockade ofthe negative co-stimulatory molecules PD-1 and CTLA-4 improves survival in primary and secondary fungal sepsis
Differential regulation of motility and immune synapses by CD28/ CTLA-4 costimulation in effector and regulatory T cells
Sequencing CTLA-4 blockade with cell-based immunotherapy for prostate cancer
Double strike approach for tumor attack: Engineering T cells using CD40L:CD28 chimeric co-stimulatory proteins for enhanced tumor targeting in adoptive cell therapy
Immunotherapies targeting stimulatory pathways and beyond
Combined targeting of co-stimulatory (OX40) and co-inhibitory (CTLA-4) pathways elicits potent effector T cells capable of driving robust anti-tumor immunity
Inhibition of STAT3 augments antitumor efficacy of anti-CTLA-4 treatment against prostate cancer